南非农村高流行区二线蛋白酶抑制剂方案治疗HIV-1的病毒学结局
中位随访178.7人年,病毒学失败(VF)发生率为12.9/100人年(n=23),其中56.5%在中位8.0个月后重新抑制;结核治疗与VF独立相关(SHR 11.50,95%CI 3.92-33.74;
要点
- 二线bPI方案病毒学失败率较高(12.9/100人年),需重视病毒载量监测。
- 超过半数失败者在中位8.0个月后重新抑制,支持持续病毒载量监测的价值。
- 结核治疗与二线bPI方案病毒学失败独立相关(SHR 11.50)。
核心结论
- 在此高结核负担农村地区,二线bPI方案病毒学失败常见,但过半失败者可重新抑制,结核治疗与VF独立相关。
主要发现
- 病毒学失败发生率为12.9/100人年(n=23),删失时VF患病率为17.8%。
- 结核治疗与VF相关(SHR 11.50,95%CI 3.92-33.74;P<.001)。
关键数值与推荐
- VF定义为启动bPI方案≥6个月后血浆病毒载量>1000 copies/mL。
- 二线方案为利托那韦boosted洛匹那韦联合齐多夫定或替诺福韦加lamivudine或emtricitabine。
- 采用竞争风险回归(考虑死亡和失访)估计亚分布风险比(SHR)。
临床怎么用
- 对二线bPI方案治疗者应加强病毒载量监测,以识别可重新抑制的失败者。
- 合并结核治疗者需警惕病毒学失败风险,优化ART管理。
局限性
- 观察性队列设计,不能确立因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV) worldwide. Maximizing their effectiveness is imperative. METHODS: This cohort study was nested within the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) cluster-randomized trial in rural KwaZulu-Natal, South Africa. We prospectively investigated risk factors for virological failure (VF) of bPI-based ART in the combined study arms. VF was defined by a plasma viral load >1000 copies/mL ≥6 months after initiating bPI-based ART. Cumulative incidence of VF was estimated and competing risk regression was used to derive the subdistribution hazard ratio (SHR) of the associations between VF and patient clinical and demographic factors, taking into account death and loss to follow-up. RESULTS: One hundred one participants contributed 178.7 person-years of follow-up. Sixty-five percent were female; the median age was 37.4 years. Second-line ART regimens were based on ritonavir-boosted lopinavir, combined with zidovudine or tenofovir plus lamivudine or emtricitabine. The incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23), and prevalence of VF at censoring was 17.8%. Thirteen of these 23 (56.5%) virologic failures resuppressed after a median of 8.0 months (interquartile range, 2.8-16.8 months) in this setting where viral load monitoring was available. Tuberculosis treatment was associated with VF (SHR, 11.50 [95% confidence interval, 3.92-33.74]; P < .001). CONCLUSIONS: Second-line VF was frequent in this setting. Resuppression occurred in more than half of failures, highlighting the value of viral load monitoring of second-line ART. Tuberculosis was associated with VF; therefore, novel approaches to optimize the effectiveness of PI-based ART in high-tuberculosis-burden settings are needed. CLINICAL TRIALS REGISTRATION: NCT01509508.
引用
- Collier D, Iwuji C, Derache A, et al. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. Clin Infect Dis. 2017. PMID: 28329393. doi:10.1093/cid/cix015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。